Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.55 |
| ▸ | MMP2 | P08253 | 1/20 | 0.55 |
| ▸ | MMP8 | P22894 | 1/20 | 0.55 |
| ▸ | PANK3 | Q9H999 | 5/20 | 0.51 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.43 |
| ▸ | ME2 | P23368 | 2/20 | 0.42 |
| ▸ | ME1 | P48163 | 2/20 | 0.42 |
| ▸ | ME3 | Q16798 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 4/20 | 0.41 |
| ▸ | DRD4 | P21917 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2247600 | 1.00 | MMP1 (0.55) | MMP1MMP2MMP8PANK3TRPV1 | |
| SCHEMBL2247529 | 0.89 | PANK3 (0.52) | PANK3TRPV1ME2ME1ME3 | |
| SCHEMBL2549668 | 0.89 | PANK3 (0.52) | PANK3TRPV1ME2ME1ME3 | |
| SCHEMBL2241911 | 0.89 | MMP1 (0.56) | MMP1MMP2MMP8PANK3 | |
| SCHEMBL2552328 | 0.89 | MMP1 (0.56) | MMP1MMP2MMP8PANK3 | |
| SCHEMBL2248888 | 0.85 | MMP1 (0.42) | MMP1MMP2MMP8PANK3DRD2 | |
| SCHEMBL8271398 | 0.85 | MMP1 (0.42) | MMP1MMP2MMP8PANK3DRD2 | |
| SCHEMBL11989062 | 0.85 | MMP1 (0.42) | MMP1MMP2MMP8PANK3DRD2 | |
| SCHEMBL2242116 | 0.85 | MMP1 (0.42) | MMP1MMP2MMP8PANK3DRD2 | |
| SCHEMBL8273020 | 0.85 | MMP1 (0.42) | MMP1MMP2MMP8PANK3DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263628-A1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2011-10-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263628-A1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | HNMT, HCAR2, HPGD | MMP1 812/4885MMP2 1413/4885MMP8 438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.